Cargando…
Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease
Chronic graft versus host disease (cGVHD) is a debilitating and costly complication following haemopoietic stem cell transplantation (HSCT). This study describes the economic burden associated with cGVHD. Direct costs associated with specialised healthcare utilisation (inpatient admissions and outpa...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822787/ https://www.ncbi.nlm.nih.gov/pubmed/33275188 http://dx.doi.org/10.1007/s10198-020-01249-x |
_version_ | 1783639703978770432 |
---|---|
author | Schain, Frida Batyrbekova, Nurgul Liwing, Johan Baculea, Simona Webb, Thomas Remberger, Mats Mattsson, Jonas |
author_facet | Schain, Frida Batyrbekova, Nurgul Liwing, Johan Baculea, Simona Webb, Thomas Remberger, Mats Mattsson, Jonas |
author_sort | Schain, Frida |
collection | PubMed |
description | Chronic graft versus host disease (cGVHD) is a debilitating and costly complication following haemopoietic stem cell transplantation (HSCT). This study describes the economic burden associated with cGVHD. Direct costs associated with specialised healthcare utilisation (inpatient admissions and outpatient visits), as well as indirect costs associated with sickness absence-associated productivity loss were estimated in patients who underwent allogeneic HSCT in Sweden between 2006 and 2015, linking population-based health and economic registers. To capture the period of chronic GVHD, patients were included who survived > 182 days post-HSCT (start of follow-up), and cGVHD was classified based on patient treatment records to correct for any diagnosis underreporting. Patients were classified as ‘non-cGVHD’ if they received no immunosuppressive treatment, ‘mild cGVHD’ if they received only systemic corticosteroid treatment or immunosuppressive treatment, or ‘moderate–severe cGVHD’ if they received extracorporeal photopheresis (ECP) only, corticosteroid treatment and immunosuppressive treatment, or systemic corticosteroid treatment and ECP treatments. Patients with moderate–severe cGVHD spent more time in healthcare, had higher healthcare resource costs and higher sickness absence-related productivity loss compared to patients with non- or mild cGVHD. The cumulative total costs during the first 3 years of follow-up were EUR 14,887,599, EUR 20,544,056, and EUR 47,811,835 for non-, mild, and moderate–severe groups, respectively. The long-term costs incurred with cGVHD following HSCT continue to be very high and significantly impacted by cGVHD severity. This study adds real-world health resource and economic insight relevant for policy-makers and healthcare providers when considering the clinical challenge of balancing immunosuppression to reduce cGVHD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10198-020-01249-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7822787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-78227872021-02-11 Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease Schain, Frida Batyrbekova, Nurgul Liwing, Johan Baculea, Simona Webb, Thomas Remberger, Mats Mattsson, Jonas Eur J Health Econ Original Paper Chronic graft versus host disease (cGVHD) is a debilitating and costly complication following haemopoietic stem cell transplantation (HSCT). This study describes the economic burden associated with cGVHD. Direct costs associated with specialised healthcare utilisation (inpatient admissions and outpatient visits), as well as indirect costs associated with sickness absence-associated productivity loss were estimated in patients who underwent allogeneic HSCT in Sweden between 2006 and 2015, linking population-based health and economic registers. To capture the period of chronic GVHD, patients were included who survived > 182 days post-HSCT (start of follow-up), and cGVHD was classified based on patient treatment records to correct for any diagnosis underreporting. Patients were classified as ‘non-cGVHD’ if they received no immunosuppressive treatment, ‘mild cGVHD’ if they received only systemic corticosteroid treatment or immunosuppressive treatment, or ‘moderate–severe cGVHD’ if they received extracorporeal photopheresis (ECP) only, corticosteroid treatment and immunosuppressive treatment, or systemic corticosteroid treatment and ECP treatments. Patients with moderate–severe cGVHD spent more time in healthcare, had higher healthcare resource costs and higher sickness absence-related productivity loss compared to patients with non- or mild cGVHD. The cumulative total costs during the first 3 years of follow-up were EUR 14,887,599, EUR 20,544,056, and EUR 47,811,835 for non-, mild, and moderate–severe groups, respectively. The long-term costs incurred with cGVHD following HSCT continue to be very high and significantly impacted by cGVHD severity. This study adds real-world health resource and economic insight relevant for policy-makers and healthcare providers when considering the clinical challenge of balancing immunosuppression to reduce cGVHD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10198-020-01249-x) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-12-04 2021 /pmc/articles/PMC7822787/ /pubmed/33275188 http://dx.doi.org/10.1007/s10198-020-01249-x Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Paper Schain, Frida Batyrbekova, Nurgul Liwing, Johan Baculea, Simona Webb, Thomas Remberger, Mats Mattsson, Jonas Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease |
title | Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease |
title_full | Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease |
title_fullStr | Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease |
title_full_unstemmed | Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease |
title_short | Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease |
title_sort | real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822787/ https://www.ncbi.nlm.nih.gov/pubmed/33275188 http://dx.doi.org/10.1007/s10198-020-01249-x |
work_keys_str_mv | AT schainfrida realworldstudyofdirectmedicalandindirectcostsandtimespentinhealthcareinpatientswithchronicgraftversushostdisease AT batyrbekovanurgul realworldstudyofdirectmedicalandindirectcostsandtimespentinhealthcareinpatientswithchronicgraftversushostdisease AT liwingjohan realworldstudyofdirectmedicalandindirectcostsandtimespentinhealthcareinpatientswithchronicgraftversushostdisease AT baculeasimona realworldstudyofdirectmedicalandindirectcostsandtimespentinhealthcareinpatientswithchronicgraftversushostdisease AT webbthomas realworldstudyofdirectmedicalandindirectcostsandtimespentinhealthcareinpatientswithchronicgraftversushostdisease AT rembergermats realworldstudyofdirectmedicalandindirectcostsandtimespentinhealthcareinpatientswithchronicgraftversushostdisease AT mattssonjonas realworldstudyofdirectmedicalandindirectcostsandtimespentinhealthcareinpatientswithchronicgraftversushostdisease |